lnth stock — Lantheus Holdings Overview

LNTH (Lantheus Holdings, Inc.) — Stock Overview

lnth stock is the NASDAQ ticker for Lantheus Holdings, Inc., a U.S.-based healthcare company focused on radiopharmaceutical oncology, diagnostic imaging agents, and precision diagnostics. In this article you will find a comprehensive company profile, a chronological history and milestone timeline, an overview of business operations and principal products, the research and development pipeline, financial and market data guidance, governance and legal context, competitive landscape, risk factors, and practical investor information. Readers will gain a concise yet detailed reference to support further research and monitoring of lnth stock.

As of January 25, 2026, according to Lantheus' investor relations and SEC filings, LNTH is listed on the NASDAQ exchange. This overview is time-sensitive in financial details; refer to Lantheus' investor relations page and the company's 10-Q/10-K filings for the latest numbers.

Company profile

Lantheus Holdings, Inc. is a U.S. healthcare company with a mission to deliver precision diagnostic and therapeutic solutions that improve patient outcomes. Headquartered in North Billerica, Massachusetts, the company was founded in the mid-20th century (with modern corporate forms evolving through spin-offs and reorganizations) and has focused on three core business segments:

• Radiopharmaceutical Oncology — development and commercialization of targeted imaging agents and therapeutic radiopharmaceuticals for oncology applications.
• Precision Diagnostics — diagnostic imaging agents, ultrasound enhancement agents, and products supporting PET and SPECT imaging workflows.
• Strategic Partnerships and Contract Services — manufacturing, licensing, and collaborative agreements with imaging, pharmaceutical, and biotech partners to scale production and distribution.

lnth stock reflects investor exposure to these clinical and commercial activities, which combine recurring product sales, intellectual property, and specialized manufacturing capabilities.

Name and ticker

The company's common shares trade under the ticker symbol "LNTH" on the NASDAQ exchange. The trading identifiers used by market data providers and brokerage platforms will list the equity as LNTH. Investors tracking lnth stock should verify ticker and exchange details on official market-data pages and on Lantheus' investor relations communications.

History and corporate development

Lantheus has evolved through product innovation, selective acquisitions, and strategic divestitures. The firm's corporate history includes major approvals, commercialization of diagnostic agents, and periodical portfolio adjustments to concentrate on high-growth radiopharmaceuticals and diagnostic segments.

The company has previously reorganized certain legacy businesses and executed transactions such as the divestiture of select imaging assets to sharpen its focus on radiopharmaceutical oncology and precision diagnostics. Over time, Lantheus' strategic development emphasized building a pipeline of PET imaging agents and advancing novel therapeutic radiopharmaceuticals.

Timeline of key events

• 19XX — Founding and early development of imaging agents and diagnostic products. (Historical company milestone; consult company history page for exact founding year.)
• YYYY — Regulatory approval and launch of flagship diagnostic agents that established commercial presence in medical imaging.
• YYYY — Key licensing agreements with pharmaceutical and imaging companies to co-develop or distribute imaging agents.
• YYYY — Strategic divestiture of certain legacy SPECT business units to focus resources on PET and radiopharmaceutical oncology. (See company press releases for transaction dates and terms.)
• YYYY — IPO / public listing events and subsequent secondary offerings or equity financings to support pipeline development.
• YYYY — Approval and commercialization of Pylarify (or equivalent PET imaging agents) expanding oncology imaging revenue. (Check FDA approval records for specific dates.)
• YYYY — Manufacturing scale-up and collaborations to secure radiopharmaceutical supply chain and distribution.

Note: The above timeline is illustrative. For precise dates and transaction terms, consult Lantheus' SEC filings and investor relations press releases. As of January 25, 2026, the company continues to publish verified milestone updates via its investor relations channels.

Business operations and products

Lantheus' revenue is driven by the sale of diagnostic imaging agents, radiopharmaceutical oncology products, and related services such as manufacturing and distribution partnerships. The company operates manufacturing facilities capable of handling radioisotope production and radiopharmaceutical compounding, supporting both commercial supply and clinical trial material needs.

Primary revenue streams include:

• Commercial sales of diagnostic imaging agents used in PET and SPECT imaging.
• Sales of ultrasound enhancement agents and related diagnostic consumables.
• Contract manufacturing, licensing fees, and milestone or royalty income from strategic partnerships.
• Development-stage revenues tied to research collaborations and government or institutional grants.

Radiopharmaceutical Oncology

Lantheus is known for developing and commercializing radiopharmaceutical imaging agents used in oncology to detect, stage, and manage cancer. Flagship oncology imaging agents—such as prostate-specific membrane antigen (PSMA)-targeted PET radiotracers—have substantial clinical use for prostate cancer detection and staging. These products serve important clinical use cases:

• Detection of recurrent or metastatic disease when conventional imaging is inconclusive.
• Guiding therapy selection and monitoring response to systemic or localized cancer treatments.
• Patient selection for targeted radiotherapeutics and enrollment in clinical trials.

Commercial significance: Radiopharmaceutical oncology products tend to command premium pricing due to specialized manufacturing, regulatory requirements, and clinical value. Their adoption can materially affect lnth stock performance due to revenue concentration and growth potential.

Precision Diagnostics and Imaging Agents

Lantheus' precision diagnostics portfolio includes imaging agents across PET, SPECT, and ultrasound enhancement. Examples of categories in the company's offering include:

• PET imaging agents for oncology and neurology — high-resolution tracers used in hospital and clinic PET scanners to localize disease.
• SPECT imaging agents and generators — products that support conventional nuclear medicine imaging workflows.
• Ultrasound enhancement agents (contrast agents) — microbubble products used to improve ultrasound image clarity for cardiac and liver imaging.

These diagnostic agents are used by hospitals, imaging centers, and specialty clinics and represent steady recurring revenue streams. The operational model includes distribution networks, cold-chain logistics, and time-sensitive delivery given isotope half-lives.

Strategic partnerships and services

Lantheus leverages licensing and partnership agreements to expand geographic reach, share development risk, and monetize intellectual property. Typical strategic collaborations include:

• Co-development agreements with pharmaceutical and biotech firms to test companion imaging agents paired with therapeutic candidates.
• Manufacturing and supply contracts with imaging networks and third-party radiopharmacies to guarantee product availability.
• Licensing deals where Lantheus grants rights to distribute or further develop specific imaging agents in return for upfront payments, milestones, or royalties.

In some cases, the company offers contract manufacturing services to other radiopharmaceutical developers, providing clean-room production and regulatory-compliant release testing. Partnerships with imaging system vendors and clinical networks help accelerate clinical adoption and reimbursement efforts.

Research and development / Pipeline

R&D is a critical driver for companies like Lantheus because future growth often depends on developing new radiopharmaceuticals and diagnostic agents. The company's R&D strategy focuses on oncology, with additional research targeting neurology and cardiology imaging needs.

Key R&D focus areas:

• Development of next-generation PET radiotracers with improved sensitivity and specificity for tumor detection.
• Companion diagnostics that support targeted therapies and help identify patients most likely to benefit from specific treatments.
• Radiotherapeutic programs (where applicable) that use therapeutic radioisotopes for targeted cancer cell killing.

Pipeline candidates and clinical development:

• Early- to mid-stage PET imaging agents in clinical trials for specific tumor types (e.g., prostate cancer, neuroendocrine tumors). Candidate names and phases should be checked in the latest company pipeline report and SEC filings.
• Investigator-initiated studies validating new indications or demonstrating clinical utility versus standard imaging approaches.
• Manufacturing process innovations to improve radiotracer yield, stability, and distribution reach.

R&D investments directly affect lnth stock through anticipated future revenue potential, but outcomes are intrinsically uncertain and subject to regulatory review and clinical validation.

Financial profile

The financial profile of Lantheus is relevant to investors tracking lnth stock. Important metrics include revenue trends, profitability (gross margin, operating margin), market capitalization, debt levels, and cash position. These figures are time-sensitive and should be updated from the company's latest quarterly (10-Q) and annual (10-K) reports.

General investor considerations:

• Revenue trends: Monitor the split between commercial product sales and partnership or license revenue. Growth in radiopharmaceutical oncology sales is often a prime driver.
• Profitability: Gross margins in radiopharmaceuticals can be strong but are influenced by manufacturing costs, yield, and pricing dynamics.
• Balance sheet: Cash, short-term investments, and debt levels determine runway for R&D and ability to finance manufacturing expansions.
• Capital raises: Any recent equity or debt financings dilute or alter capital structure and can materially affect lnth stock.

Note on timeliness: Specific revenue and market-cap figures change frequently. As of January 25, 2026, investors should consult Lantheus' SEC filings and major financial data providers for up-to-date metrics before making any decisions relating to lnth stock.

Historical financial performance

Historically, Lantheus has reported quarterly and annual results that reflect product sales seasonality, adoption curves for newer imaging agents, and one-off items such as divestiture gains or restructuring charges. Typical items to watch in earnings releases include:

• Year-over-year revenue growth for flagship products.
• Adjusted EBITDA and net income trends revealing operational leverage.
• Guidance revisions reflecting underlying demand or reimbursement changes.
• Cash flow from operations and capital expenditures supporting manufacturing capacity.

Earnings calls often shed light on commercial uptake, reimbursement progress, and near-term revenue drivers that influence lnth stock volatility around reporting dates.

Stock market performance and trading information

lnth stock trades on NASDAQ and is followed by equity analysts and healthcare-focused investors. Key trading considerations include share price history, volatility, 52-week range, average daily volume, free float, shares outstanding, and large share movements tied to news flow.

Investors tracking lnth stock should monitor:

• Price reactions to product approvals, label expansions, or negative regulatory news.
• Volume spikes around earnings releases and strategic announcements.
• Institutional ownership shifts reported on Schedule 13F filings and insider transactions reported on Form 4.

For active traders, technical indicators and volume patterns can inform short-term decisions; for long-term investors, pipeline milestones and commercial traction are more material.

Analyst coverage and ratings

Equity research analysts covering lnth stock typically publish rating summaries, target price ranges, and thematic research notes. Consensus ratings may include buy/hold/sell opinions and highlight catalysts such as regulatory approvals, commercial launches, or margin expansion. Investors should read analyst reports as part of broader due diligence while noting that analyst views are not guarantees of future performance.

Major shareholders and institutional ownership

Large institutional holders and insiders can influence the ownership profile of lnth stock. Common institutional holders for healthcare and small-cap equities include mutual funds, specialized healthcare-focused funds, and passive index funds. Monitoring changes in institutional ownership and insider buying or selling provides insight into sentiment among sophisticated market participants.

Corporate governance and management

Good governance practices and experienced management teams matter for companies developing regulated medical products. Lantheus' corporate governance includes a board of directors and executive leadership such as CEO, CFO, and heads of R&D and commercial operations.

Investors should review:

• Board composition: independent directors, relevant industry expertise, and committee structures (audit, compensation, nominating).
• Executive experience: leadership track record in radiopharmaceuticals, diagnostics, or pharmaceutical commercialization.
• Recent appointments or departures: changes at the CEO/CFO level can be material for lnth stock.

Transparent disclosure and consistent investor communications are positive governance signals; significant governance controversies or frequent executive turnover can increase investor risk.

Legal, regulatory and litigation matters

Radiopharmaceutical and diagnostic companies operate in a heavily regulated environment. Key legal and regulatory considerations for Lantheus include FDA approvals and post-market compliance, manufacturing inspections, patent disputes, and potential class-action litigation related to disclosure or product claims.

Important items to monitor:

• FDA approvals or Complete Response Letters (CRLs) impacting product commercialization timelines.
• Manufacturing inspections and remediation plans affecting supply continuity.
• Intellectual property litigation defending key patents for imaging agents and manufacturing processes.
• Any material legal settlements or regulatory fines disclosed in SEC filings.

Material legal or regulatory actions can be market-moving for lnth stock and are routinely disclosed in periodic filings and press releases.

Controversies and significant market-moving events

Investors should be aware of historical controversies or one-off events that had material impact on the company or lnth stock price, such as product recalls, unexpected trial failures, or major divestitures. Market-moving events often include:

• Major sell-offs following negative clinical trial data or regulatory setbacks.
• Lawsuits challenging patents or commercial practices.
• Material restatements of financial results or disclosure lapses.

When such events occur, review company statements and regulatory filings to understand remediation plans and long-term implications for the business and lnth stock.

Investor relations and communications

Lantheus maintains an investor relations portal where official filings, earnings releases, SEC periodic reports (10-Q and 10-K), and corporate presentations are published. Investors tracking lnth stock should:

• Consult the investor relations site for press releases, upcoming events, and presentation slides.
• Review SEC filings for detailed financial statements and risk-factor disclosures.
• Listen to earnings calls and read management commentary for forward-looking context (noting that forward-looking statements are subject to risks and disclaimers).

Primary sources to verify facts include the company's investor relations page (investor.lantheus.com), the U.S. Securities and Exchange Commission filings, and major financial media and data providers. As of January 25, 2026, investors should refer to the latest published 10-Q or 10-K for current metrics.

Dividends, share repurchases and capital allocation

Historically, companies in the radiopharmaceutical and diagnostics space may prioritize reinvesting free cash flow into R&D and manufacturing capacity. Lantheus' capital allocation approach should be assessed via public disclosures:

• Dividend policy: Check whether the company pays regular dividends; such decisions are described in annual reports or dividend notices.
• Share repurchases: Any share buyback programs or authorizations are material to earnings-per-share dynamics and dilution management.
• Use of proceeds from financings: Equity or debt raises are commonly used to fund pipeline development or plant expansions.

Investors should check the most recent annual report and investor presentations for explicit capital allocation policies and any board-authorized buyback programs affecting lnth stock.

Competitive landscape and market position

Lantheus competes in radiopharmaceuticals and imaging with other specialized companies, large diagnostics manufacturers, and emerging biotech firms. Competitive factors include:

• Product differentiation: tracer specificity, imaging resolution, and convenience of use.
• Manufacturing scale and reliability: ability to supply time-sensitive radiopharmaceuticals at scale.
• Regulatory and reimbursement support: payer acceptance and established coding affect adoption.
• Partnerships and distribution networks: alliances with imaging centers and health systems increase reach.

Competitive strengths for Lantheus may include an established commercial organization in imaging agents, manufacturing expertise, and an expanding oncology-focused pipeline. Risks include competition from other radiotracer developers and potential generic or biosimilar entrants for non-proprietary agents.

Risk factors

Investors in lnth stock should consider principal risks disclosed by the company and common to the radiopharmaceutical sector:

• Regulatory risk: Approval delays, CRLs, or post-market requirements can materially affect timelines and revenue.
• Commercialization risk: Limited adoption, reimbursement challenges, or competing products can hinder sales growth.
• Manufacturing and supply risk: Radiopharmaceuticals have short half-lives and complex supply chains; any production disruption can impact sales.
• Concentration risk: Heavy reliance on a small number of products or a single geographic market increases earnings volatility.
• Litigation and IP risk: Patent disputes or infringement claims could disrupt exclusivity and revenues.
• Capital risk: Need for continued R&D funding could require equity dilution or debt issuance.

These risks are typically discussed in detail in the company's periodic SEC filings and should be reviewed regularly by stakeholders in lnth stock.

Recent news and developments

This section should be updated frequently to reflect recent earnings reports, regulatory approvals, strategic transactions (licensing deals, acquisitions, divestitures), major supply agreements, and leadership changes. Example items to include when they occur:

• Quarterly earnings results and management commentary on product uptake.
• FDA approvals, PMA/510(k) clearances (for diagnostic devices), or label expansions for imaging agents.
• New partnership agreements with pharmaceutical or imaging companies to co-develop agents or expand distribution.
• Manufacturing capacity expansions or new contract-manufacturing agreements.

As of January 25, 2026, check Lantheus' investor relations press releases and SEC filings for the latest verified developments affecting lnth stock.

See also

• Radiopharmaceuticals
• PET imaging
• Diagnostic imaging agents
• Healthcare stocks listed on NASDAQ

References and further reading

Primary sources for verification and further research include:

• Lantheus' investor relations materials and corporate press releases (investor.lantheus.com).
• U.S. Securities and Exchange Commission filings (10-Q, 10-K, 8-K) for financial statements and material event disclosures.
• Major financial news outlets and market-data providers for share-price history and analyst coverage.

As of January 25, 2026, the latest official filings and press releases are the authoritative sources for figures and corporate statements related to lnth stock.

External links

For up-to-date company information consult:

• Lantheus official corporate website and investor relations page.
• Market-data pages for LNTH on major financial data providers and NASDAQ listings.

Note: When researching or trading lnth stock, consider using Bitget's research tools and trading interface to monitor company news and market prices. Bitget provides market data and a platform for equities research and trading.

Notes on maintenance

Financial and market-data sections in this article are time-sensitive and should include a date-of-last-update. Update this page after each quarterly earnings release or any material corporate event affecting lnth stock. For validation, reference the company's latest SEC filings and verified press releases.

Practical next steps for readers

• Review Lantheus' most recent 10-Q/10-K for up-to-date financial metrics and risk disclosures before acting on information about lnth stock.
• Monitor official press releases and earnings-call transcripts for real-time management guidance and pipeline updates.
• Track analyst reports for consensus views and target-price changes, while maintaining independent evaluation of clinical and commercial risks.

To continue your research or to monitor lnth stock prices, consider using Bitget's market research tools and watchlist features to stay current with filings and news.

Disclaimer: This article is informational and not investment advice. It summarizes publicly available information and directs readers to primary sources for verification. Always consult professional financial and legal advisors before making investment decisions regarding lnth stock.